Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

AntengeneCorp-license

More Like This

PR Newswire associated0

Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025

PR Newswire associated0

Antengene Announces 2025 Interim Results with Encouraging Clinical Data and Progress in TCE Platform

PR Newswire associated0

Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

PR Newswire associated0

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

Business Wire logo

Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody

Business Wire logo

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager